Key Takeaways
Altimmune Inc. (NASDAQ: ALT) reported a first-quarter loss of $0.18 per share, narrower than the $0.25 loss analysts expected, and strengthened its balance sheet to fund operations into 2029. The company generated no revenue, as is typical for a clinical-stage biopharmaceutical firm.
"We're entering a new phase for the company with the right team in place and a very strong balance sheet," President and Chief Executive Officer Jerome Durso said in a statement. "We’re now focused on execution and believe we’re well-positioned to successfully execute our strategy."
The company's net loss for the quarter was $22.6 million, compared to a net loss of $19.6 million in the prior-year period. Altimmune's cash, cash equivalents, and short-term investments stood at approximately $535 million on a pro forma basis as of April 30, following a $225 million public offering. This cash position is expected to fund the company through its planned Phase 3 data readout for pemvidutide in MASH.
Altimmune is advancing its lead candidate, pemvidutide, a dual glucagon and GLP-1 agonist, across several liver disease indications. The company announced it will initiate its global Phase 3 PERFORMA trial for metabolic dysfunction-associated steatohepatitis (MASH) in the second half of 2026, with 52-week biopsy data expected in 2029.
Management highlighted the drug's tolerability profile as a key differentiator from competing GLP-1 therapies, which have been associated with higher rates of gastrointestinal side effects and treatment discontinuation.
The company also expects to report top-line data from its Phase 2 RECLAIM trial of pemvidutide in alcohol use disorder (AUD) in the third quarter of 2026. Enrollment for another Phase 2 trial in alcohol-associated liver disease (ALD) is expected to be completed in the same quarter.
The extended cash runway to 2029 de-risks the company’s financial position, allowing it to focus on executing its late-stage clinical trials for pemvidutide. Investors will be closely watching for the upcoming Phase 2 AUD data in Q3 2026 and the initiation of the Phase 3 MASH trial as key milestones.
This article is for informational purposes only and does not constitute investment advice.
